| abstract |
A method for the production of high purity gadobutrol with a purity (according to HPLC) of more than 99.7, or 99.8, or 99.9%, and use for the preparation of a pharmaceutical preparation for parenteral administration is described. The method was carried out using definitely controlled crystallization conditions. The most recent advances in gadolinium-containing MR contrast agents (EP 0448191 B1, patent CA 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include MRI contrast agent gadobutrol (Gadovist® 1.0), which has been approved for a long time in Europe and later also in the United States under the name Gadovist®. |